Heparosan-based biomaterials and coatings and methods of production and use thereof
View Patent ↗The presently claimed and disclosed invention relates to biomaterial compositions that include an isolated heparosan polymer. The presently claimed and disclosed invention also relates to kits containing such biomaterial compositions, as well as to methods of producing such biomaterial compositions. The presently claimed and disclosed invention further relates to methods of using such biomaterial compositions as surface coatings for implants as well as for augmenting tissues.
1. A method of augmenting tissue in a mammalian patient, comprising the step of:
administering an isolated heparosan polymer to a mammalian patient, wherein the isolated heparosan polymer is biocompatible with the mammalian patient and biologically inert in extracellular compartments of the mammalian patient, and wherein the isolated heparosan polymer is represented by the structure (-GlcUA-beta1,4-GlcNAc-alpha-1,4-) n , wherein n is a positive integer greater than or equal to 1.
2. The method of claim 1 , wherein the isolated heparosan polymer is not degraded by hyaluronidases or heparanases in the mammalian patient.
3. The method of claim 1 , wherein the isolated heparosan polymer is recombinantly produced.
4. The method of claim 1 , wherein the isolated heparosan polymer is in a liquid state.
5. The method of claim 1 , wherein, prior to administration to the mammalian patient, the isolated heparosan polymer is in at least one form selected from the group consisting of a gel, semi-solid, particulate state, and combinations thereof.
6. The method of claim 1 , wherein the isolated heparosan polymer is attached to a substrate selected from the group consisting of silica, silicon, semiconductors, glass, polymers, metals, gold, copper, stainless steel, nickel, aluminum, titanium, thermosensitive alloys and combinations thereof.
7. The method of claim 6 , wherein the isolated heparosan polymer is covalently attached to the substrate.
8. The method of claim 6 , wherein the isolated heparosan polymer is non-covalently attached to the substrate.
9. The method of claim 1 , wherein the isolated heparosan polymer has, as compared to at least one of heparin, heparan sulfate, and hvaluronan, increased biostability in an extracellular matrix of the mammalian patient.
10. The method of claim 1 , wherein the isolated heparosan polymer is cross-linked.
11. The method of claim 1 , wherein the isolated heparosan polymer is not cross-linked.
12. The method of claim 1 , wherein the isolated heparosan polymer is unsulfated and unepimerized.
13. A method of augmenting tissue in a mammalian patient, comprising the step of:
injecting an isolated heparosan polymer into a mammalian patient, wherein the isolated heparosan polymer is biocompatible with the mammalian patient and biologically inert in extracellular compartments of the mammalian patient, and wherein the isolated heparosan polymer is represented by the structure (-GlcUA-beta1,4-GlcNAc-alpha-1,4-) n , wherein n is a positive integer greater than or equal to 1.
14. The method of claim 13 , wherein the isolated heparosan polymer is in a liquid state.
15. The method of claim 13 , wherein the isolated heparosan polymer is not degraded by hyaluronidases or heparanases in the mammalian patient.
16. The method of claim 13 , wherein the isolated heparosan polymer is recombinantly produced.
17. The method of claim 13 , wherein the isolated heparosan polymer has, as compared to at least one of heparin, heparan sulfate, and hvaluronan, increased biostability in an extracellular matrix of the mammalian patient.
18. The method of claim 13 , wherein the isolated heparosan polymer is cross-linked.
19. The method of claim 13 , wherein the isolated heparosan polymer is not cross-linked.
20. The method of claim 13 , wherein the isolated heparosan polymer is unsulfated and unepimerized.
21. A method of augmenting tissue in a mammalian patient, comprising the step of:
implanting an isolated heparosan polymer into a mammalian patient, wherein the isolated heparosan polymer is biocompatible with the mammalian patient and biologically inert in extracellular compartments of the mammalian patient, and wherein the isolated heparosan polymer is represented by the structure (-GlcUA-beta1,4-GlcNAc-alpha-1,4-) n , wherein n is a positive integer greater than or equal to 1.
22. The method of claim 21 , wherein the isolated heparosan polymer is not degraded by hyaluronidases or heparanases in the mammalian patient.
23. The method of claim 21 , wherein the isolated heparosan polymer is recombinantly produced.
24. The method of claim 21 , wherein, prior to administration to the mammalian patient, isolated heparosan polymer is in at least one form selected from the group consisting of a gel, semi-solid, particulate state, and combinations thereof.
25. The method of claim 21 , wherein the isolated heparosan polymer is attached to a substrate selected from the group consisting of silica, silicon, semiconductors, glass, polymers, metals, gold, copper, stainless steel, nickel, aluminum, titanium, thermosensitive alloys and combinations thereof.
26. The method of claim 25 , wherein the isolated heparosan polymer is covalently attached to the substrate.
27. The method of claim 25 , wherein the isolated heparosan polymer is non-covalently attached to the substrate.
28. The method of claim 21 , wherein the isolated heparosan polymer has, as compared to at least one of heparin, heparan sulfate, and hyaluronan, increased biostability in an extracellular matrix of the mammalian patient.
29. The method of claim 21 , wherein the isolated heparosan polymer is cross-linked.
30. The method of claim 21 , wherein the isolated heparosan polymer is not cross-linked.
31. The method of claim 21 , wherein the isolated heparosan polymer is unsulfated and unepimerized.
32. A method, comprising the step of:
administering an isolated heparosan polymer into a mammalian patient, wherein the isolated heparosan polymer is biocompatible with the mammalian patient and biologically inert in extracellular compartments of the mammalian patient, and wherein the isolated heparosan polymer is represented by the structure (-GlcUA-beta1,4-GlcNAc-alpha-1,4-) n , wherein n is a positive integer greater than or equal to 1.
33. The method of claim 32 , wherein the isolated heparosan polymer has, as compared to at least one of heparin, heparan sulfate, and hyaluronan, increased biostability in an extracellular matrix of the mammalian patient when compared to heparin, heparan sulfate and hyaluronan.
34. The method of claim 32 , wherein the isolated heparosan polymer is cross-linked.
35. The method of claim 32 , wherein the isolated heparosan polymer is not cross-linked.
36. The method of claim 32 , wherein the isolated heparosan polymer is unsulfated and unepimerized.